inPractice® - Elbasvir/Grazoprevir

Management of Hepatitis C Infection

Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
Editor In Chief: Stefan Zeuzem, MD
Last Reviewed: 1/9/21 (What's New)

Summary

Elbasvir/grazoprevir is approved for use in patients with genotype 1 or 4 HCV infection with compensated cirrhosis^{[FDA Elbasvir Grazoprevir]}
In phase III trials, high SVR12 rates with 12-week and 16-week regimens in patients with genotype 1, 4, or 6 HCV infection and cirrhosis
- Treatment-naive patients treated with elbasvir/grazoprevir for 12 weeks: 97%^{[Zeuzem 2015]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Hepatitis C-Treatment